aTYR PHARMA Book Value Per Share Growth & History (ATYR)
aTYR PHARMA's book value per share was $0.69 for fiscal 2025.
View full aTYR PHARMA company overviewaTYR PHARMA annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.69 | -$0.14 | −17.38% |
| 2024 | 2024-12-31 | $0.83 | -$0.60 | −41.84% |
| 2023 | 2023-12-31 | $1.43 | -$0.99 | −40.87% |
| 2022 | 2022-12-31 | $2.42 | -$1.51 | −38.40% |
| 2021 | 2021-12-31 | $3.93 | $1.06 | +36.92% |
| 2020 | 2020-12-31 | $2.87 | -$2.57 | −47.23% |
| 2019 | 2019-12-31 | $5.44 | -$9.95 | −64.63% |
| 2018 | 2018-12-31 | $15.39 | -$14.80 | −49.03% |
| 2017 | 2017-12-31 | $30.19 | -$6.84 | −18.46% |
| 2016 | 2016-12-31 | $37.03 | -$31.02 | −45.59% |
| 2015 | 2015-12-31 | $68.05 | $1,468.39 | — |
| 2014 | 2014-12-31 | -$1,400.34 | -$187.44 | — |
| 2013 | 2013-12-31 | -$1,212.89 | — | — |
aTYR PHARMA quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.50 | -$0.31 | −38.28% |
| Q1 2026 | 2026-03-31 | $0.59 | -$0.25 | −29.93% |
| Q4 2025 | 2025-12-31 | $0.69 | -$0.14 | −17.38% |
| Q3 2025 | 2025-09-30 | $0.82 | -$0.04 | −4.97% |
| Q2 2025 | 2025-06-30 | $0.81 | -$0.27 | −25.15% |
| Q1 2025 | 2025-03-31 | $0.84 | -$0.39 | −31.76% |
| Q4 2024 | 2024-12-31 | $0.83 | -$0.60 | −41.84% |
| Q3 2024 | 2024-09-30 | $0.86 | -$0.82 | −48.71% |
| Q2 2024 | 2024-06-30 | $1.08 | -$0.79 | −42.19% |
| Q1 2024 | 2024-03-31 | $1.24 | -$0.82 | −40.01% |
| Q4 2023 | 2023-12-31 | $1.43 | -$0.99 | −40.87% |
| Q3 2023 | 2023-09-30 | $1.68 | -$0.98 | −36.85% |
| Q2 2023 | 2023-06-30 | $1.86 | -$1.22 | −39.54% |
| Q1 2023 | 2023-03-31 | $2.06 | -$1.45 | −41.35% |
| Q4 2022 | 2022-12-31 | $2.42 | -$1.51 | −38.40% |
| Q3 2022 | 2022-09-30 | $2.66 | -$1.57 | −37.13% |
| Q2 2022 | 2022-06-30 | $3.08 | $0.57 | +22.58% |
| Q1 2022 | 2022-03-31 | $3.51 | $0.41 | +13.16% |
| Q4 2021 | 2021-12-31 | $3.93 | $1.06 | +36.92% |
| Q3 2021 | 2021-09-30 | $4.23 | $1.01 | +31.47% |
| Q2 2021 | 2021-06-30 | $2.51 | -$1.33 | −34.69% |
| Q1 2021 | 2021-03-31 | $3.10 | -$1.40 | −31.09% |
| Q4 2020 | 2020-12-31 | $2.87 | -$2.57 | −47.23% |
| Q3 2020 | 2020-09-30 | $3.22 | -$3.65 | −53.16% |
| Q2 2020 | 2020-06-30 | $3.85 | -$4.71 | −55.05% |
| Q1 2020 | 2020-03-31 | $4.50 | -$4.52 | −50.08% |
| Q4 2019 | 2019-12-31 | $5.44 | -$9.95 | −64.63% |
| Q3 2019 | 2019-09-30 | $6.87 | -$11.40 | −62.39% |
| Q2 2019 | 2019-06-30 | $8.56 | -$12.72 | −59.77% |
| Q1 2019 | 2019-03-31 | $9.02 | -$11.88 | −56.83% |
| Q4 2018 | 2018-12-31 | $15.39 | -$14.80 | −49.03% |
| Q3 2018 | 2018-09-30 | $18.27 | -$15.78 | −46.34% |
| Q2 2018 | 2018-06-30 | $21.28 | -$2.23 | −9.51% |
| Q1 2018 | 2018-03-31 | $20.90 | -$8.95 | −29.98% |
| Q4 2017 | 2017-12-31 | $30.19 | -$6.84 | −18.46% |
| Q3 2017 | 2017-09-30 | $34.06 | -$9.62 | −22.02% |
| Q2 2017 | 2017-06-30 | $23.51 | -$27.59 | −53.99% |
| Q1 2017 | 2017-03-31 | $29.85 | -$29.53 | −49.73% |
| Q4 2016 | 2016-12-31 | $37.03 | -$31.02 | −45.59% |
| Q3 2016 | 2016-09-30 | $43.67 | -$32.82 | −42.91% |
| Q2 2016 | 2016-06-30 | $51.10 | -$31.42 | −38.08% |
| Q1 2016 | 2016-03-31 | $59.38 | $1,391.85 | — |
| Q4 2015 | 2015-12-31 | $68.05 | $1,468.39 | — |
| Q3 2015 | 2015-09-30 | $76.49 | — | — |
| Q2 2015 | 2015-06-30 | $82.52 | — | — |
| Q1 2015 | 2015-03-31 | -$1,332.47 | — | — |
| Q4 2014 | 2014-12-31 | -$1,400.34 | — | — |
aTYR PHARMA book value per share trends
Over the last five fiscal years, aTYR PHARMA's book value per share decreased from $2.87 to $0.69, a change of -$2.18. The latest reported quarter, Q2 2026, shows $0.50.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review aTYR PHARMA source filings ↗